

DECLARATION

I, Pieter Anton Ekermans declare that this research report is my own work. It is being submitted for the degree of Master of Medicine in the branch of Clinical Pathology in the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at this or any other University.

..... [Signature of candidate]

..... day of, 2012

Dedicated to our esteemed Professor in Chemical Pathology

Janice Paiker

PUBLICATIONS AND PRESENTATIONS

No publications and presentations have arisen from this research report at the time of submission for examination.

ACKNOWLEDGEMENTS

Professor Adriano Dusé and Dr Jaya George, supervisors of this study and research report.

Mr Floyd Olsen from the Receiving Office at the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) National Health Laboratory Service (NHLS) branch.

Dr Natalie Beylis from the NHLS Mycobacteriology Referral Laboratory, Braamfontein.

Mrs Sue Candy and Mrs Alex Jennings from the Corporate Data Warehouse (CDW) of the NHLS.

Mr John Waters and his staff from the archives at CMJAH.

Dr Hendrick Emanuel Van Deventer from Lancet Laboratories.

TABLE OF CONTENTS

	Page
DECLARATION	ii
DEDICATION	iii
PUBLICATIONS AND PRESENTATIONS	iv
ACKNOWLEDGEMENTS	v
TABLE OF CONTENTS	vi
LIST OF FIGURES	xi
LIST OF TABLES	xii
LIST OF ABBREVIATIONS	xiv
ABSTRACT	xvi
1.0 INTRODUCTION, ENCOMPASSING REVIEW OF THE LITERATURE	1
1.1 Physiology	1
1.1.1 Isoforms	1
1.2 Clinical significance	2
1.3 Measurement	3
1.4 Major health care concerns in South Africa	3
1.5 Extra-pulmonary TB	4
1.6 Diagnosis of TBM	5
1.7 Use of ADA in the context of TBM	6
1.8 Critical assessment and interpretation of the literature on the use of CSF ADA in the diagnosis of TBM	7

1.8.1	Total number of participants/specimens	8
1.8.2	Age of participants	8
1.8.3	Definition of TBM and control groups	9
1.8.4	HIV status	10
1.8.5	Cut-offs for CSF ADA	11
1.8.6	ADA assay types	11
1.9	Prediction rules	12
1.10	Aims of study	13
2.0	MATERIALS AND METHODS	14
2.1	Introduction	14
2.2	Data collection procedure	16
2.2.1	Laboratory data collection	16
2.2.2	Clinical data collection	18
2.2.3	Checking procedures	18
2.3	Inclusion and exclusion criteria	19
2.4	Total population considered in this study	20
2.5	Patient categorisation	20
2.5.1	Demographics	20
2.5.2	Categorisation of pathologies	22
2.5.2.1	Pathologies involving the CSF	23
2.5.2.1.1	TBM	23
2.5.2.1.1.1	Confirmed TBM	23
2.5.2.1.1.2	Suspected TBM	23

2.5.2.1.2	Non-TBM pathologies	23
2.5.2.1.2.1	Infective	24
2.5.2.1.2.1.1	Confirmed bacterial meningitis	24
2.5.2.1.2.1.2	Suspected bacterial meningitis	24
2.5.2.1.2.1.3	Confirmed brain abscess	24
2.5.2.1.2.1.4	Confirmed cerebral malaria	24
2.5.2.1.2.1.5	Suspected cerebritis	25
2.5.2.1.2.1.6	Confirmed cryptococcal meningitis (<i>Cryptococcus neoformans</i>)	25
2.5.2.1.2.1.7	Suspected meningitis	25
2.5.2.1.2.1.8	Confirmed mixed infection	25
2.5.2.1.2.1.9	Suspected mixed infection	26
2.5.2.1.2.1.10	Confirmed <i>Mycobacterium</i> other than tuberculosis (MOTT) meningitis	26
2.5.2.1.2.1.11	Suspected neurocysticercosis	26
2.5.2.1.2.1.12	Confirmed neurosyphilis	26
2.5.2.1.2.1.13	Confirmed toxoplasmosis	26
2.5.2.1.2.1.14	Confirmed ventriculitis	26
2.5.2.1.2.1.15	Confirmed viral meningitis / encephalitis	27
2.5.2.1.2.1.16	Suspected viral meningitis / encephalitis	27
2.5.2.1.2.2	Non-infective	27
2.5.2.1.2.2.1	Carcinomatous meningitis	27
2.5.2.1.2.2.2	Medical – related pathology	27
2.5.2.1.2.2.3	Psychiatric disorders (and psychiatric – related disorders)	27
2.5.2.1.2.2.4	Surgical – related pathology	28
2.5.2.1.2.2.5	Toxicology	28

2.5.2.2	Pathologies not involving the CSF	28
2.5.2.2.1	Other	28
2.5.2.3	No diagnosis made	28
2.6	CSF cell counts and chemistry	28
2.7	ADA assay utilized in this study	29
2.8	Ethics	31
2.9	Statistical analysis of data collected	31
3.0	RESULTS	34
3.1	Demographics and Patient categorisation	34
3.2	CSF cell counts and CSF chemistry for categories	43
3.3	TB culture data	44
3.4	Ranges of CSF ADA for categories	46
3.5.	Common infective intra-cranial pathologies compared	52
3.6	Statistical comparison of demographic groups regarding CSF ADA results	52
3.6.1	Total population (n=3548)	52
3.6.2	TBM category (n=92)	53
3.6.3	Comparison of 'Confirmed TBM' CSF ADA results to all CSF ADA results for patients where TB culture on CSF was absent and or negative	55
3.7	ROC curve analysis	56
3.7.1	ROC curve analysis performed on all patients that had both an ADA and culture for TB requested on a CSF specimen (n=1490)	56
3.7.2	ROC curve analysis performed on the individual demographic categories	

	for all patients that had both an ADA and culture for TB requested on a CSF	58
3.8	Prediction rule	60
3.9	Clinical research case definition for TBM	61
3.9.1	CSF ADA results for the total population of n=3548	61
3.9.2	CSF ADA results of the ‘Suspected TBM’ group compared to the clinical research case definition.	61
3.10	Specimen integrity	62
4.0	DISCUSSION AND CONCLUSION	65
4.1	Limitations	70
4.2	Other issues	77
4.3	Conclusion	79
	APPENDICES	80
	Appendix A: Clinical research case definition by Marais, <i>et al.</i> , 2010.	80
	Appendix B: Package inserts for ADA assay, quality control material and calibrator.	83
	Appendix C: Ethics clearance certificate.	89
	Appendix D: CSF cell counts and CSF chemistry	90
	REFERENCES	92

LIST OF FIGURES

	Page
Figure 2.1: Categorisation of pathologies identified for this study.	22
Figure 3.1: Non-parametric / non-Gaussian distribution of CSF ADA results.	46
Figure 3.2: CSF ADA values for each of the categories, with emphasis on outliers.	48
Figure 3.3: CSF ADA values for each of the categories, with emphasis on the 95% distribution of values.	49
Figure 3.4: ROC plot for all patients that had both an ADA and a culture for TB requested on a CSF specimen.	56
Figure 3.5: CSF ADA values plotted according to the specimen integrity comments for each sample.	63

LIST OF TABLES

	Page
Table 2.1: Summary of how the study population was generated.	16
Table 2.2: Laboratory information collected.	17
Table 2.3: Main demographic categories.	20
Table 3.1: Demographic categories for the total population of 3548 patients.	34
Table 3.2: Number of patients per category in the total population (n=3548).	35
Table 3.3: Clinical scenarios where suspected TBM was considered by clinicians.	36
Table 3.4: Culture results for the 'Confirmed bacterial meningitis' category.	37
Table 3.5: Summary of cases categorised as 'Confirmed viral meningitis / encephalitis'.	40
Table 3.6: TB culture data amongst patients used in this study.	45
Table 3.7: CSF ADA values (in U/L) for each of the categories.	50
Table 3.8: Mixed infections classified as 'Confirmed TBM'.	51
Table 3.9: Statistical comparison of the 8 demographic groups regarding their CSF ADA results (total population, n=3548).	53
Table 3.10: Statistical comparison of the 8 demographic groups regarding their CSF ADA results ('Confirmed TBM' category, n=92).	54
Table 3.11: Statistical comparison of 'Confirmed TBM' CSF ADA results with all CSF ADA results for patients where TB culture on CSF was absent and or negative (in U/L).	55
Table 3.12: Derived values and ratios at a CSF ADA cut-off of 2.0 U/L.	57

Table 3.13:	Target and actual sensitivities and specificities at different CSF ADA levels.	58
Table 3.14:	ROC curve results for each of the demographic categories in the population of n=1490.	59
Table 3.15:	CSF ADA results for the clinical research case definition (in U/L).	61
Table 3.16:	Specimen integrity comments for CSF ADA requests (in U/L).	62
Table 3.17:	Specimen integrity comments for CSF ADA requests in the ‘TBM category’.	64
Table A1:	TBM case definition.	80
Table A2:	Diagnostic criteria for classification of definite, probable and possible TBM.	81
Table D1:	CSF cell counts for the individual categories.	90
Table D2:	CSF chemistry for the individual categories.	91

LIST OF ABBREVIATIONS

ADA	Adenosine deaminase
AFB	Acid-fast bacilli
AIDS	Acquired Immunodeficiency syndrome
AUC	Area under the curve
CDW	Corporate Data Warehouse
CI	Confidence interval
CLAT	Cryptococcal latex antigen test
CMJAH	Charlotte Maxeke Johannesburg Academic Hospital
CMV	Cytomegalovirus
CSF	Cerebrospinal fluid
CT	Computerised tomography
CXR(s)	Chest X-ray(s)
dx	Diagnosis
EBV	Epstein-Barr virus
ELISA	Enzyme-linked immunosorbent assay
HIV	Human Immunodeficiency virus
IQR(s)	Interquartile range(s)
JC virus	John Cunningham virus
MOTT	<i>Mycobacterium</i> other than tuberculosis
NAAT	Nucleic acid amplification techniques
NHLS	National Health Laboratory Service
PCR	Polymerase chain reaction
ROC	Receiver operating characteristic

RPR	Rapid plasma reagin
TB	Tuberculosis
TBM	Meningitis due to <i>Mycobacterium tuberculosis</i>
TPHA	<i>Treponema pallidum</i> haemagglutination
UNAIDS	Joint United Nations Programme on HIV / AIDS
VDRL	Venereal Disease Reference Laboratory
WHO	World Health Organisation

ABSTRACT

Introduction:

The diagnosis of meningitis due to *Mycobacterium tuberculosis* (TBM) in general can be extremely difficult in the absence of culture confirmation. A non-definitive test such as adenosine deaminase (ADA) could potentially assist in this regard, although its current value for the diagnosis of TBM remains unclear. The literature on the usefulness of ADA measurement in CSF to assist in the diagnosis of TBM shows inconsistencies especially from an analytical point of view regarding the actual ADA assay methodology.

Methods:

Clinical and laboratory data relating to cerebrospinal fluid (CSF) ADA requests during 2009 and 2010 at the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) were extracted from patient files and the National Health Laboratory Service (NHLS) laboratory information system. An optimal cut-off for CSF ADA for the diagnosis of TBM was calculated using Receiver Operating Characteristic (ROC) curve analysis. In addition, the performance of CSF ADA in different infective and non-infective categories was assessed. Specifically the performance of CSF ADA was compared between the 'Confirmed TBM' category and the categories for 'Confirmed bacterial meningitis', 'Confirmed ventriculitis', 'Confirmed cryptococcal meningitis', and 'Confirmed viral meningitis / encephalitis'. An attempt was made to develop a prediction rule using the data collected, including the CSF ADA result, to improve the clinical diagnosis of TBM in the absence of culture confirmation.

Results:

Total CSF ADA requests considered for these 2 years amounted to 3548. Of these 1490 accounted for patients who had both a CSF ADA and a culture for mycobacteria requested. The optimal CSF ADA cut-off to assist in the diagnosis of TBM was calculated at 2.0 U/l (AUC of 0.86; 95% CI of 0.82 – 0.89; p – value of < 0.0001). The sensitivity at this cut-off was 85.9% and the specificity was 77.7%. A considerable overlap was noted in the 95% distribution of CSF ADA values as well as the outliers for each of the categories considered. No statistically significant difference was noted between the ‘Confirmed TBM’ and the ‘Confirmed bacterial meningitis’ categories as well as between the ‘Confirmed TBM’ and the ‘Confirmed ventriculitis’ categories. Stepwise logistic regression analysis failed to produce a combination of factors with appropriate performance characteristics to be used as a prediction rule.

Discussion and Conclusion:

The CSF ADA cut-off determined in this study is unusually low. This cut-off as well as those reported in other studies, in addition to the actual CSF ADA result, are of dubious value in the diagnosis of TBM and may potentially mislead clinicians. Fundamental issues of specimen integrity, ADA assay standardisation and the overlap in the performance of the assay in different diagnostic categories (especially between ‘Confirmed TBM’ and ‘Confirmed bacterial meningitis’) affect interpretation of the CSF ADA result. An inadequate number of correlations between variables chosen possibly prevented generation of an acceptable prediction rule that included CSF ADA.